Medi+Care Restore

ReCell™ treatment is an innovative device that enables a doctor to apply a patient’s own skin cells, collected from a small sample to restore the area.

Medi + Care Restore in conjuction with Regenerative medicine company Avita Medical Limited is pleased to advise that new positive, statistically significant results have been obtained in a ReCell(R) Spray-on Skin(R) trial in patients suffering with depigmented skin lesions.

Avita Medical's lead product, ReCell, a single-use autologous cell harvesting technology, has been used successfully in place of costly permanent laboratory facilities, which require special licensure, in the treatment of patients with vitiligo or piebaldism.

Avita Medical new results highlight ReCell as an innovative and effective treatment for a large, under-served population.

"It's estimated that around one in 200 people will suffer from Vitiligo. In Europe alone that represents more than 3. 7 million patients.

ReCell technology works through the delivery of viable, pigment-producing cells harvested from a piece of the patient's own normally-pigmented skin and is administered by spraying the cells onto the affected area.

The study involved 10 patients who participated in a randomised, within-subject controlled pilot trial facilitated by the Netherlands Institute for Pigment Disorders (Stichting Nederlands Instituut voor Pigmentstoornissen or SNIP).

Albert Wolkerstorfer M. D. from the SNIP who was the Principal Investigator of the trial and is also affiliated with the University of Amsterdam, said that the results of the study were certainly a positive indication that ReCell can be used effectively in the treating patients suffering from vitiligo and piebaldism disorders.

"The study has provided positive clinical data on the tolerability and effectiveness of ReCell in the management and treatment of these disorders.

In both vitiligo and piebaldism, the cells that are responsible for skin pigmentation no longer function as they should, resulting in uneven skin pigment and discolouration in patients. There is no universally accepted medical standard of care for the disorders and patients are usually provided with a combination of topical and phototherapy treatments.